Women’s Health Is Society’s Wealth: Unlocking Economic Value When Bridging the Gender Health Gap
October 29, 2025
When the facts are loud and clear: investing in women’s health could unlock $1 trillion in global gross domestic product annually by 2040, prevent 24 million female life years lost to disability, and yield exponential returns to economy for every investment across obstetrics and gynecology, female and maternal health, immunology, neurology, cardiology, and oncology.
Improving global health equity has been increasingly recognized as a strategic priority for different stakeholders in healthcare,1 including policymakers, industry, governments, investors, and global health organizations. Beyond an ethical and human rights imperative, reducing health inequities and ensuring that everyone has a fair opportunity to achieve their full health potential — independent of socioeconomic status, sex, gender, geography, or race/ethnicity — leads to economic and societal benefits and resilient healthcare systems.2 Although progress continues to be made toward improving general health outcomes, Cytel researchers have found that this has not translated equally for men and women.3
The gender health gap: A global health crisis
Attention to women’s health inequities and the potential economic impact from closing this health gap remain largely unnoticed. The gender health gap — the long-standing, unfair differences in health outcomes between women and men — has been only recently recognized as a medical and healthcare issue. The underinvestment in female health research, the absence of systematic data collection to understand and document the unique biological needs of females and assess disparities, as well as biases in male-dominant clinical trial programs have all contributed to the neglect of women’s health issues. The survival paradox is documented, with women outliving men but experiencing poorer general health, including mental health; recent data showing that women live approximately five years longer than men does not adequately categorize the fact that women spend more than one-quarter of their lives in poor health.4, 5 This health gap is a global health crisis that affects women of all ages to varying extents depending on geography and income levels.4
The gender health gap is generally defined by the conditions that affect women uniquely, differently, or disproportionately, and are not limited to those related to sexual and reproductive health.4 For example, women from the general population are at significantly greater risk of mental health disorders (e.g., depression, suicide) than men, and women with type 2 diabetes mellitus have a disproportionally higher risk of adverse cardiac events, including mortality.6 Men, on the other hand, are significantly more likely to have adverse events after specific types of surgeries and higher mortality after COVID-19.6 Despite the fact that cardiovascular disease is the top cause of death for women in the US, males outnumber females two to one in related clinical trials.7
Quantifying the economic benefit of closing the women’s health gap
Quantifying the economic benefit of closing the women’s health gap for societies and economies is important for several reasons and makes visible the “invisible” topic of women and their health. By attaching a measurable economic gain — such as productivity gains, increased workforce participation, reduced healthcare spending — policymakers and investors can grasp the tangible impact on global economies and growth. As financial pressures are restraining healthcare spending, prioritization of resource allocation where interventions yield the greatest returns to economies, such as women’s health, may be placed higher in the list of investment priorities.7 Therefore, systematic efforts to quantify the economic value when bridging the gender health gap will push reframing health equity as a driver for inclusive and sustainable growth, making it a strategic imperative for governments and businesses and overturn the negligible investment in women’s health (only 5% in 2020).8
Our findings: The value of investment to improve women’s health
We conducted a comprehensive literature review that aimed to systematically investigate and summarize quantitative evidence on the economic impact of investments to close the women’s health gap globally. We identified robust evidence to demonstrate that when investment is made to improve women’s health, there is return to this investment by bringing back higher value to economies.
A recent report jointly published by the World Economic Forum and the McKinsey Health Institute, for example, highlights that investments in addressing the women’s health gap could not only extend life years and healthy life years, but also have the potential to boost the global economy by $1 trillion annually by 2040.4 These findings were supported by an additional impact analysis conducted by Women’s Health Access Matters across three indications: rheumatoid arthritis, coronary artery disease, and Alzheimer’s disease. Key findings indicated that an investment of $300 million in women’s health research across these three diseases would conservatively result in a $13 billion return to the US economy.7
Over the past 70 years, the influx of women into the workforce has been closely linked to economic growth.4 Since nearly half of the health burden affects women in their working years, this can have serious consequences for the income-earning potential of women, causing a ripple effect on society.4 Economic benefits in the same direction were also documented by simulation studies in other countries such as the United Kingdom whereas limited data were identified for low- and middle-income countries.
We are committed to standing at the forefront of assessing public policy trends and critical policy matters that highlight emerging challenges and seizing opportunities for improving public health. Some examples include our environmental scan of publicly available data repositories to address disparities in healthcare decision-making,9 an umbrella review of the impacts of climate change on maternal health and birth outcomes,10 and blueprints for collective action to close the women health gap.
Interested in learning more?
Grammati Sarri, Lilia Leisle, and Jeffrey M. Muir will be at the upcoming ISPOR Europe conference in Glasgow, Scotland, where they will present “The Economic Case for Gender Equity: How Closing the Women’s Health Gap Benefits Healthcare Systems and Economies” on Wednesday, November 12, 2025, from 9 to 11:30 a.m. Register below to book a meeting or visit us at Booth #1024 to connect with our experts:
Book a meeting!Subscribe to our newsletter
Grammati Sarri
Vice President, Evidence, Value, Access, and Health Policy
Grammati Sarri is Vice President, Evidence, Value, Access, and Health Policy at Cytel. Grammati is a dedicated health policy professional with a strong background in public health, data analysis and policy development from her previous roles in academia, National Institute for Health and Care Excellence, international consultancies, and clinical research organizations. Grammati is passionate about connecting data and methods to patient outcomes and developing innovative solutions that can bridge research and implementation by improving healthcare access and equity, including improving women’s health.
At Cytel, Grammati leads a group of specialists in public health policy, health equity, and value-based healthcare, bringing health economics and outcomes research activities closer to evidence-based policymaking. Grammati also leads Cytel’s EU JCA Taskforce and holds senior positions in international organizations (ISPE, ISPOR, EU-funded AI trial).
Read full employee bio
Lilia Leisle
Senior Research Consultant
Lilia Leisle is Senior Research Consultant in the Access team at Cytel. Lilia’s special interest lies in health equity research promoting new value elements in health technology assessment (HTA) related to gender equity and environmental sustainability. She has co-authored publications covering sex-related health disparities, the impact of climate change on maternal health and newborn outcomes, as well as consideration of health equity and environmental impact in HTA. As a core member of Cytel’s EU Joint Clinical Assessment (JCA) Taskforce, she participates in diverse EU JCA-related projects, mainly focusing on the JCA scoping process. She leads EU JCA PICO simulations and Market Access strategy projects, including assessments of evidence generation plans, clinical development plans, and target product profiles from the HTA and payers’ perspective mostly across European markets.
Read full employee bio
Jeffrey M. Muir
Research Principal, Evidence Review and Software
Jeffrey M. Muir is Research Principal, Evidence Review and Software at Cytel. Jeff is a clinical epidemiologist and clinician focused on real-world evidence in the pharmaceutical and medical device industries. His current research centers around real-world evidence to support drug development and health policy, including health equity, expanding value elements in health technology assessment and health economics and outcomes research focused on providing evidence-based support for policy- and decision-makers in the health policy and HTA sectors.
Read full employee bioClaim your free 30-minute strategy session
Book a free, no-obligation strategy session with a Cytel expert to get advice on how to improve your drug’s probability of success and plot a clearer route to market.
